Safety and efficacy of high ‐dose methotrexate for osteosarcoma in adolescents compared with young adults

ConclusionAge over 18  years correlates with delayed methotrexate clearance and fewer administered doses of methotrexate, without increased toxicity. The potential benefit of HDMTX in young adults with osteosarcoma may outweigh toxicity risks.

Source: Cancer Medicine - December 22, 2018 Category: Cancer & Oncology Authors: Brittany Wippel, Kenneth R. Gundle, Theresa Dang, Jillian Paxton, Joseph Bubalo, Linda Stork, Rongwei Fu, Christopher W. Ryan, Lara E. Davis Tags: ORIGINAL RESEARCH Source Type: research